Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Patiromer allows more CKD patients to continue on spironolactone

Key clinical point: Patients with chronic kidney disease and resistant hypertension may stay on spironolactone longer with patiromer.

Major finding: After 12 weeks, 86% of the patiromer patients remained on spironolactone, vs. 66% of the placebo patients, for a significant between-group difference of 19.5% (P less than .0001).

Study details: AMBER, a randomized trial.

Disclosures: Funding for AMBER came from Relypsa, which markets patiromer (Veltassa). Dr. Williams reported consulting for Relypsa during the conduct of the study.

Citation:

Williams B. HFSA 2019.